Anti-mutiertes Calreticulin / CALR (Hu) aus Maus (CAL2) – unkonj.

218,00 

100 µl

Voraussichtliche Lieferzeit: 1 Werktag

zum Vergleich hinzufügen
Artikelnummer: DIA-CAL-100 Kategorien: , , Schlagwörter: , ,
  • Übersicht
    ArtikelnummerDIA-CAL-100
    Spezifität

    Spezies-Reaktivität

    Immunogen

    Wirtsspezies

    Isotyp

    Klon

    Klonalität (Mono-/Polyklonal)

    Anwendung

    ,

    Konjugation

    Verdünnung

    Format

    , , ,

    Produktlinie / Thema

    Zweckbestimmung

    Temperatur - Lagerung

    Temperatur - Transport

    Suchcode

    , ,

    Hersteller / Marke

    Uniprot_ID

    Gene_ID

    Alias

    , , , , , , , , , , , , , ,

  • Datenblätter und Downloads
  • Weitere Produktinformationen

    Practical Implementation:

    CAL2 labels the megakaryocytes in myeloproliferative neoplasms (essential thrombocythaemia (ET) and primary myelofibrosis (PMF)) with CALR mutation and enables to distinguish ET and PMF with CALR mutation from polycythemia vera (PV), from CALR mutation negative ET and PMF and from reactive bone marrow.

    Why is CAL2 able to detect all known types of CALR mutations?

    All types of CALR mutation result in a novel C-terminus. This harbors a common epitope expressed in all kinds of CALR mutations. The CAL2 antibody is directed against this common epitope. Therefore, it can be concluded that the CAL2 antibody is able to detect all CALR mutations.

    CAL2 IHC of four PMF cases:

    A and C: Selective staining of mutated CALR protein in megakaryocytes of two PMF cases, respectively in prefibrotic phase and in fibrotic phase, in which Sanger sequencing detected a CALR mutation.

    B and D: Absent CAL2 staining in two PMF cases, respectively in prefibrotic and in fibrotic phase, both without molecularly detected mutated CALR. The fibrotic stroma remains unstained (C and D).

    Selective staining of mutated CALR protein in megakaryocytes of a PMF case, in prefibrotic phase in which Sanger sequencing detected a CALR mutation.

    A

    Immunohistochemical staining (IHC) with anti-mutated CALR Antibody (clone CAL2) - dianova

    B

    Selective staining of mutated CALR protein in megakaryocytes of a PMF case, in fibrotic phase in which Sanger sequencing detected a CALR mutation.

    C

    Immunohistochemical staining (IHC) with anti-mutated CALR Antibody (clone CAL2) - dianova

    D

    References

    1. Bonifacio M et al. CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations. BLOOD 128: 3122, 2016
    2. Nomani L et al. CAL2 Immunohisto-chemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms. Am J Clin Pathol. 146(4): 431-438, 2016.
    3. Andrici J et al. Mutation specific immuno-histochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms. Pathology 48(4): 319-324, 2016
    4. Stein, H et al. A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin embedded bone marrow sections. Leukemia 2015, accepted for publication.
    5. Nangalia J et al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med 369(25): 2391-2405, 2013.
    6. Klampfl T et al. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. N Engl J Med 369(25): 2379-2390, 2013.

  • Bilder
    Antikörper Anti-mutiertes Calreticulin / CALR (Hu) aus Maus (CAL2)
    Selektive IHC-Färbung von mutiertem CALRETICULIN in Megakaryozyten bei früher primärer Myelofibrose (Klon CAL2).
    Antikörper Anti-mutiertes Calreticulin / CALR (Hu) aus Maus (CAL2)
    Selektive IHC-Färbung von mutiertem CALRETICULIN in Megakaryozyten bei essentieller Thrombozythämie (Klon CAL2).
    Antikörper Anti-mutiertes Calreticulin / CALR (Hu) aus Maus (CAL2)
    IHC-Nachweis aller Arten von CALRETICULIN Mutationen in MPNs (FFPE Knochenmarkbiopsate) mit dem monklonalen Antikörper CAL2.
Kontakt
Bestellung:
Tel.: +49 (0)40 / 450670
Beratung:
Tel.: +49 (0)40 / 450670